Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: Challenges and feasibility

IDrugs

Volumn 11, Issue 7, 2008, Pages 497-501

  Knop, F K ^a,b   Holst, J J ^b   Vilsboll T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; APOPTOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; FEASIBILITY STUDY; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GLUCAGON RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RISK REDUCTION; SIDE EFFECT; VOMITING; WAIST HIP RATIO; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MOLECULAR MIMICRY; SULFONYLUREA COMPOUNDS;

EID: 46749113089     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. No Authors Listed: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care (2002) 25(Suppl 1):S5-S20.
2. Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia (2003) 46(1):3-19.
3. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 29(1):46-52.
4. Janbon M, Chaptal J, Vedel A, Schaap J: Accidents hypoglycé miques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med (1942) 441:21-22.
5. Henquin JC: The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work? Diabetologia (1992) 35(10):907-912.
6. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med (2006) 355(23):2427-2443.
7. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY: Sulfonylurea-induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab (2005) 90(1):501-506.
8. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 36(8):741-744.
9. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity and β-cell function in type 2 diabetes: A parallel-group study. Lancet (2002) 359(9309):824-830.
10. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 24(1):275-286.
11. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP: Efficacy and safety of the dipeptidyl peptidase 4 inhibitor sitagliptin, compared with the sulfonylurea glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2007) 9(2):194-205.
12. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J: Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes (2006) 114(8):417-423.